Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PolyMedix -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (6)	6/7/2010 1:12:30 AM
From: tnsaf	Read Replies (1) \| Respond to of 77

Hi, Rick. XOMA's approach with Neuprex was to modify a piece of a natural protein with bactericidal properties and with the ability to neutralize lipopolysaccharide and to preserve these characteristics. PolyMedix has taken a model of how defensins work and constructed hundreds of small molecules with antimicrobial activity. If only an antibiotic is wanted, this seems a better approach. The small molecules should be cheaper to make and maybe more effective than Neuprex. But Neuprex has the added ability to neutralize LPS. An article from the American Society of Microbiology - 101st General Meeting 20-24 May 2001, Orlando, FL, talks about BPI and defensins as antibiotics. This Google search turned it up.